Scinai Immunotherapeutics Ltd.
SCNI
$2.44
-$0.0734-2.92%
NASDAQ
| 06/30/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -54.51% | -33.39% | 0.10% | -11.48% | -17.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -100.28% | -- | -- | -- |
| Total Operating Expenses | -10.94% | -72.95% | -2.73% | -20.47% | 21.84% |
| Operating Income | 21.89% | 72.95% | 2.73% | 20.47% | -21.84% |
| Income Before Tax | 38.28% | -340.62% | -165.03% | -26.11% | -42.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 38.28% | -340.62% | -165.03% | -26.11% | -42.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 38.28% | -340.62% | -165.03% | -26.11% | -42.02% |
| EBIT | 21.89% | 72.95% | 2.73% | 20.47% | -21.84% |
| EBITDA | 37.46% | 73.64% | 2.93% | 21.49% | -22.85% |
| EPS Basic | 67.28% | -185.08% | -127.07% | 30.32% | 18.34% |
| Normalized Basic EPS | 67.28% | -185.09% | -- | 30.32% | 18.34% |
| EPS Diluted | 67.28% | 17.91% | -127.07% | 30.32% | 9.73% |
| Normalized Diluted EPS | 67.28% | -185.09% | -- | 30.32% | 18.34% |
| Average Basic Shares Outstanding | 88.64% | 54.53% | 140.12% | 81.04% | 73.90% |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |